BR112017027414B1 - Derivados hidroxiéster, processo para prepará-los e composições farmacêuticas os contendo - Google Patents

Derivados hidroxiéster, processo para prepará-los e composições farmacêuticas os contendo Download PDF

Info

Publication number
BR112017027414B1
BR112017027414B1 BR112017027414-0A BR112017027414A BR112017027414B1 BR 112017027414 B1 BR112017027414 B1 BR 112017027414B1 BR 112017027414 A BR112017027414 A BR 112017027414A BR 112017027414 B1 BR112017027414 B1 BR 112017027414B1
Authority
BR
Brazil
Prior art keywords
group
alkyl
branched
linear
phenyl
Prior art date
Application number
BR112017027414-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112017027414A2 (pt
Inventor
Zoltan SZLAVIK
András Kotschy
Maïa CHANRION
Didier DEMARLES
Olivier Geneste
James Edward Paul Davidson
James Brooke Murray
Szabolcs Sipos
Attila Paczal
Balázs Bálint
Original Assignee
Les Laboratoires Servier
Vernalis (R&D) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier, Vernalis (R&D) Limited filed Critical Les Laboratoires Servier
Publication of BR112017027414A2 publication Critical patent/BR112017027414A2/pt
Publication of BR112017027414B1 publication Critical patent/BR112017027414B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112017027414-0A 2015-06-23 2016-06-22 Derivados hidroxiéster, processo para prepará-los e composições farmacêuticas os contendo BR112017027414B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1555752A FR3037957B1 (fr) 2015-06-23 2015-06-23 Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR1555752 2015-06-23
PCT/EP2016/064433 WO2016207225A1 (en) 2015-06-23 2016-06-22 New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
BR112017027414A2 BR112017027414A2 (pt) 2018-08-28
BR112017027414B1 true BR112017027414B1 (pt) 2023-12-19

Family

ID=54608634

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017027414-0A BR112017027414B1 (pt) 2015-06-23 2016-06-22 Derivados hidroxiéster, processo para prepará-los e composições farmacêuticas os contendo

Country Status (43)

Country Link
US (2) US10227358B2 (cg-RX-API-DMAC10.html)
EP (1) EP3313851B1 (cg-RX-API-DMAC10.html)
JP (1) JP6741697B2 (cg-RX-API-DMAC10.html)
KR (1) KR102718253B1 (cg-RX-API-DMAC10.html)
CN (1) CN107709333B (cg-RX-API-DMAC10.html)
AR (1) AR105103A1 (cg-RX-API-DMAC10.html)
AU (1) AU2016282836B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017027414B1 (cg-RX-API-DMAC10.html)
CA (1) CA2990088C (cg-RX-API-DMAC10.html)
CL (1) CL2017003258A1 (cg-RX-API-DMAC10.html)
CO (1) CO2017012786A2 (cg-RX-API-DMAC10.html)
CR (1) CR20170564A (cg-RX-API-DMAC10.html)
CU (1) CU20170160A7 (cg-RX-API-DMAC10.html)
CY (1) CY1122542T1 (cg-RX-API-DMAC10.html)
DK (1) DK3313851T3 (cg-RX-API-DMAC10.html)
EA (1) EA033266B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP17081744A (cg-RX-API-DMAC10.html)
ES (1) ES2759480T3 (cg-RX-API-DMAC10.html)
FR (1) FR3037957B1 (cg-RX-API-DMAC10.html)
GE (2) GEAP201914678A (cg-RX-API-DMAC10.html)
HK (1) HK1249506A1 (cg-RX-API-DMAC10.html)
HR (1) HRP20200107T1 (cg-RX-API-DMAC10.html)
HU (1) HUE047889T2 (cg-RX-API-DMAC10.html)
IL (1) IL256270A (cg-RX-API-DMAC10.html)
JO (1) JO3675B1 (cg-RX-API-DMAC10.html)
MA (1) MA42239B1 (cg-RX-API-DMAC10.html)
MD (1) MD3313851T2 (cg-RX-API-DMAC10.html)
MX (1) MX372716B (cg-RX-API-DMAC10.html)
MY (1) MY190561A (cg-RX-API-DMAC10.html)
PE (1) PE20180742A1 (cg-RX-API-DMAC10.html)
PH (1) PH12017502246A1 (cg-RX-API-DMAC10.html)
PL (1) PL3313851T3 (cg-RX-API-DMAC10.html)
PT (1) PT3313851T (cg-RX-API-DMAC10.html)
RS (1) RS59904B1 (cg-RX-API-DMAC10.html)
RU (1) RU2734418C2 (cg-RX-API-DMAC10.html)
SI (1) SI3313851T1 (cg-RX-API-DMAC10.html)
SV (1) SV2017005587A (cg-RX-API-DMAC10.html)
TN (1) TN2017000511A1 (cg-RX-API-DMAC10.html)
TW (1) TWI604844B (cg-RX-API-DMAC10.html)
UA (1) UA122228C2 (cg-RX-API-DMAC10.html)
UY (1) UY36736A (cg-RX-API-DMAC10.html)
WO (1) WO2016207225A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201708460B (cg-RX-API-DMAC10.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2018015526A1 (en) 2016-07-22 2018-01-25 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
WO2018126898A1 (zh) * 2017-01-05 2018-07-12 河南美泰宝生物制药有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
MX385115B (es) * 2017-01-06 2025-03-14 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta.
IL271475B2 (en) * 2017-06-22 2023-09-01 Servier Lab Combination of mcl-1 inhibitor and standard medical treatment for hematological cancer, uses and pharmaceutical preparations
CR20200124A (es) 2017-08-15 2020-09-28 Abbvie Inc Inhibidores macrocíclicos de mcl-1 y métodos de uso
AU2018317828A1 (en) * 2017-08-15 2020-04-02 AbbVie Deutschland GmbH & Co. KG Macrocyclic MCL-1 inhibitors and methods of use
CN111372936B (zh) * 2017-11-23 2022-12-02 北京赛林泰医药技术有限公司 Mcl-1选择性抑制剂及其制备和用途
CN108424417B (zh) * 2017-12-21 2019-09-20 河南真实生物科技有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
CN110964034B (zh) * 2018-09-29 2022-04-12 江苏恒瑞医药股份有限公司 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
TWI849001B (zh) 2018-11-14 2024-07-21 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合,其用途及醫藥組合物
CN111187277B (zh) * 2018-11-14 2022-04-12 江苏恒瑞医药股份有限公司 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
US12129261B2 (en) * 2018-12-06 2024-10-29 Les Laboratoires Servier Crystalline forms of a MCL-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them
AU2020279979A1 (en) 2019-05-20 2021-11-25 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2020254299A1 (en) 2019-06-17 2020-12-24 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
WO2021067827A1 (en) * 2019-10-03 2021-04-08 California Institute Of Technology Mcl1 inhibitors and uses thereof
JP2023553808A (ja) 2020-11-24 2023-12-26 ノバルティス アーゲー Mcl-1阻害剤抗体-薬物コンジュゲートおよび使用方法
WO2022216946A1 (en) * 2021-04-07 2022-10-13 California Institute Of Technology Mcl1 inhibitors and uses thereof
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合
JP7900421B2 (ja) 2021-06-11 2026-08-04 ギリアード サイエンシーズ, インコーポレイテッド Mcl-1阻害剤と抗がん剤との組み合わせ
CN113651663B (zh) * 2021-08-20 2024-03-29 浙大宁波理工学院 一种氘代芳香羰基类化合物的制备方法
US20240401146A1 (en) 2021-10-06 2024-12-05 Institut National de la Santé et de la Recherche Médicale Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
IL317101A (en) 2022-05-20 2025-01-01 Novartis Ag Antibody-drug conjugates of anticancer compounds and methods of using them
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
UY40985A (es) 2023-11-22 2025-06-30 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗il-1rap結合結構域及其抗體-藥物偶聯物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
ES2559779T3 (es) * 2003-08-29 2016-02-15 Vernalis (R&D) Limited Compuestos de pirimidotiofeno
MX2010009729A (es) * 2008-03-05 2010-12-21 Methylgene Inc Inhibidores de actividad de proteina tirosina quinasa.
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PH12017502246B1 (en) 2018-05-28
US10227358B2 (en) 2019-03-12
MY190561A (en) 2022-04-27
KR20180019223A (ko) 2018-02-23
US10711010B2 (en) 2020-07-14
IL256270A (en) 2018-02-28
HRP20200107T1 (hr) 2020-04-03
EP3313851B1 (en) 2019-11-06
SV2017005587A (es) 2018-04-11
NZ738455A (en) 2024-03-22
UY36736A (es) 2016-12-30
EP3313851A1 (en) 2018-05-02
ZA201708460B (en) 2021-06-30
PE20180742A1 (es) 2018-04-27
JP2018522855A (ja) 2018-08-16
CA2990088A1 (en) 2016-12-29
GEP20207074B (en) 2020-03-10
AU2016282836A1 (en) 2018-01-18
TW201709911A (zh) 2017-03-16
JP6741697B2 (ja) 2020-08-19
UA122228C2 (uk) 2020-10-12
DK3313851T3 (da) 2020-01-27
MD3313851T2 (ro) 2020-02-29
JO3675B1 (ar) 2020-08-27
MA42239B1 (fr) 2020-02-28
HK1254657A1 (en) 2019-07-26
ECSP17081744A (es) 2018-02-28
CY1122542T1 (el) 2021-01-27
ES2759480T3 (es) 2020-05-11
CN107709333B (zh) 2021-01-01
US20180170947A1 (en) 2018-06-21
CN107709333A (zh) 2018-02-16
CO2017012786A2 (es) 2018-04-10
PL3313851T3 (pl) 2020-05-18
FR3037957A1 (cg-RX-API-DMAC10.html) 2016-12-30
AR105103A1 (es) 2017-09-06
TN2017000511A1 (en) 2019-04-12
MX372716B (es) 2020-05-28
FR3037957B1 (fr) 2019-01-25
WO2016207225A1 (en) 2016-12-29
KR102718253B1 (ko) 2024-10-16
TWI604844B (zh) 2017-11-11
CA2990088C (en) 2021-04-13
RU2018102365A (ru) 2019-07-23
CR20170564A (es) 2018-02-20
AU2016282836B2 (en) 2020-07-09
US20190161496A1 (en) 2019-05-30
PH12017502246A1 (en) 2018-05-28
GEAP201914678A (en) 2019-11-11
HUE047889T2 (hu) 2020-05-28
RU2734418C2 (ru) 2020-10-16
EA033266B1 (ru) 2019-09-30
MX2017016997A (es) 2018-09-07
SI3313851T1 (sl) 2020-03-31
RS59904B1 (sr) 2020-03-31
EA201890125A1 (ru) 2018-06-29
RU2018102365A3 (cg-RX-API-DMAC10.html) 2019-09-23
CU20170160A7 (es) 2018-05-08
PT3313851T (pt) 2020-01-06
HK1249506A1 (zh) 2018-11-02
CL2017003258A1 (es) 2018-06-01
BR112017027414A2 (pt) 2018-08-28

Similar Documents

Publication Publication Date Title
RU2734418C2 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
JP6871275B2 (ja) 新規アンモニウム誘導体、それを調製するためのプロセス及びそれを含有する医薬組成物
KR102620905B1 (ko) 신규한 아미노산 유도체, 이의 제조방법, 및 이를 함유한 약제 조성물
EP3313817B1 (en) Bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
CN114728949A (zh) 作为激酶抑制剂的杂环化合物及其用途
OA18889A (en) New Hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
HK1254657B (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
BR112017027645B1 (pt) Derivados de aminoácido, processo para sua preparação,composições farmacêuticas contendoos, combinação e uso dos mesmos
HK40000743A (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
HK40000743B (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
BR112017027470B1 (pt) Derivados bicíclicos, processo para sua preparação, composições farmacêuticas que os contêm, combinação e uso dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/06/2016, OBSERVADAS AS CONDICOES LEGAIS